Skip to main content
SpringerLink
Log in

mCRPC: Viele zirkulierende Tumorzellen – schlechte Prognose

  • Literatur kompakt_Urogenitale Tumoren
  • Published:
Im Focus Onkologie Aims and scope

Verschiedene Studien hatten gezeigt, dass zirkulierende Tumorzellen einen prädiktiven Wert beim metastasierten kastrationsresistenten Prostatakarzinom (mCRPC) haben. Eine Phase-III-Studie befasste sich nun mit der Aussagekraft zirkulierender Tumorzellen unter einer Docetaxel-haltigen Therapie.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Goldkorn A et al. Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2014;32(11): 1136-42.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Judith Neumaier

Authors
  1. Judith Neumaier
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Neumaier, J. mCRPC: Viele zirkulierende Tumorzellen – schlechte Prognose. Im Focus Onkologie 17, 28 (2014). https://doi.org/10.1007/s15015-014-1215-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-014-1215-x

Search

Navigation